13F Holdings
中文EN

BSX BOSTON SCIENTIFIC CORP

Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 885725 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY8.9%
TTM net income YoY25.1%
TTM EPS YoY26.7%
Revenue 3-yr CAGR15.3%
Net income 3-yr CAGR41.8%

Margins

Gross margin69.1%
Operating margin18.7%
Net margin16.6%
FCF margin15.8%
EBITDA margin25.5%

Returns

ROE14.3%
ROA7.9%
ROIC (approx.)10.6%
Asset turnover0.48x

Leverage & solvency

Liabilities / assets43.1%
Debt / equity0.47x
Current ratio1.36x
Interest coverage10.46x

Cash quality & payout

Operating cash flow / net income1.21x
Accruals ratio-1.7%
Payout ratio—
Capex / revenue4.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY2025*2025-12-31FY2024*2024-12-31FY2023*2023-12-31FY2022*2022-12-31FY2021*2021-12-31
Income statement
Revenue$20.07B$16.75B$14.24B$12.68B$11.89B
Cost of revenue$6.22B$5.26B$4.34B$3.96B$3.71B
Gross profit$13.85B$11.49B$9.90B$8.73B$8.18B
R&D expense$2.05B$1.61B$1.41B$1.32B$1.20B
SG&A expense$6.89B$5.98B$5.19B$4.52B$4.36B
Operating income$3.61B$2.60B$2.34B$1.65B$1.20B
Interest expense$349.00M$305.00M$265.00M$470.00M$341.00M
Pretax income$3.38B$2.28B$1.99B$1.14B$1.08B
Income tax$493.00M$436.00M$393.00M$443.00M$36.00M
Net income$2.90B$1.85B$1.59B$698.00M$1.04B
EBITDA$4.98B$3.87B$3.54B$2.79B$2.29B
EPS (basic)1.961.261.080.450.69
EPS (diluted)1.941.251.070.450.69
Weighted avg. shares (diluted)1.49B1.49B1.46B1.44B1.43B
Balance sheet
Cash & equivalents$1.97B$606.00M$865.00M$1.13B$2.17B
Inventory$2.94B$2.81B$2.48B$1.87B$1.61B
Current assets$8.79B$6.92B$6.51B$5.76B$6.32B
PP&E, net$4.04B$3.29B$2.86B$2.45B$2.25B
Goodwill$18.28B$17.09B$14.39B$12.92B$11.99B
Intangibles$7.02B$6.68B$6.00B$5.90B$6.12B
Total assets$43.67B$39.40B$35.14B$32.47B$32.23B
Current liabilities$5.44B$6.40B$4.93B$3.80B$4.27B
Short-term debt$299.00M$1.78B$531.00M$20.00M$261.00M
Long-term debt$11.14B$8.97B$8.57B$8.91B$8.80B
Total debt$11.44B$10.75B$9.10B$8.94B$9.06B
Total liabilities$19.20B$17.39B$15.61B$14.90B$15.61B
Shareholders' equity$24.23B$21.77B$19.28B$17.57B$16.62B
Net debt$9.47B$10.14B$8.24B$7.81B$6.90B
Cash flow statement
Operating cash flow$4.53B$3.44B$2.50B$1.53B$1.87B
Capital expenditure$876.00M$790.00M$711.00M$588.00M$554.00M
Free cash flow$3.66B$2.65B$1.79B$938.00M$1.32B
Investing cash flow-$2.64B-$5.69B-$2.57B-$2.01B-$1.60B
Financing cash flow-$395.00M$1.81B$5.00M-$548.00M-$95.00M
Depreciation & amortization$1.37B$1.27B$1.20B$1.14B$1.09B
Stock-based compensation$299.00M$266.00M$233.00M$220.00M$194.00M
Dividends paid—$0$28.00M$55.00M$55.00M
Share buybacks———$0$0

Free plan shows the latest 5 periods; Pro shows all 19 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.